Fortitude Advisory Group’s Gilead Sciences GILD Stock Holding History

Fortitude Advisory Group’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$223K	Buy	1,769 +115	+7%	+$15.2K	0.09%	206
2026 Q1	$231K	Sell	1,654 -510	-24%	-$71.4K	0.1%	189
2025 Q4	$266K	Buy	2,164 +33	+2%	+$4.01K	0.11%	161
2025 Q3	$237K	Buy	+2,131	New	+$242K	0.13%	168
2022 Q2	–	Sell	-2,304	Closed	-$137K	–	611
2022 Q1	$137K	Buy	2,304 +1,664	+260%	+$106K	0.07%	283
2021 Q4	$48K	Buy	+640	New	+$44.1K	0.02%	561

Other funds holding GILD

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

ECSS

Eurizon Capital SGR SpA Milan $37.3B AUM

CIM

Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

Fortitude Advisory Group's GILD Position: Q2 2026 in Review

Fortitude Advisory Group increased its Gilead Sciences (GILD) stake by 7% in Q2 2026, buying an estimated $15.2K and bringing the position to 1,769 shares worth $223K. The position accounts for 0.09% of the portfolio, ranked #206.

Fortitude Advisory Group first reported a position in GILD in Q4 2021 and has held it in 6 quarters since. The position peaked at $266K in Q4 2025. 879 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Fortitude Advisory Group held 1,769 shares of Gilead Sciences worth $223K as of Q2 2026.
Fortitude Advisory Group bought 115 Gilead Sciences shares in Q2 2026, an estimated $15.2K.
Gilead Sciences made up 0.09% of Fortitude Advisory Group's portfolio in Q2 2026, its #206 holding.
Fortitude Advisory Group first reported a position in Gilead Sciences in Q4 2021 and has held it in 6 quarters since.
Fortitude Advisory Group's Gilead Sciences position peaked at $266K in Q4 2025.
879 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Fortitude Advisory Group's 13F filing for Q2 2026, filed 22 Jul 2026.